Table of Contents

    Topic review

    5HTTLPR Genetic Variant

    Subjects: Genetics
    View times: 49


    Major Depressive Disorder (MDD) is a disease that involves biological, psychological, and social interactions. Studies have shown the importance of genetics contribution to MDD development. The SCL6A4 protein (5HTTLPR) functions transporting serotonin, a neurotransmitter linked to mood and emotion, to the synaptic cleft. Hence, this study seeks a better comprehension of the 5HTTLPR genetic variant association with MDD and its influence nervous system through a literature review.



    Characterized by sadness, loss of interest or pleasure, feelings of guilt or low self-esteem, altered sleep and appetite, tiredness or lack of concentration, depression is a common mental disorder and one of the foremost causes of disability worldwide[1][2][3][4]. It tends to affect more women than men and may lead to suicide[1].

    The causes of Major Depressive Disorder (MDD) are compound and far from being understood, as it involves biological, psychological, and social interactions. The genetic contribution to MDD is approximately 35%, with heredity having the highest percentage. These findings suggest that different genetic variables may contribute to the risk of developing MDD[5][6][7][8].

    The 5-hydroxytryptamine transporter (5HTT), encoded by SLC6A4 (solute carrier family 6, member 4), also known as sodium-dependent serotonin transporter, is found in the plasmatic membrane and transports the neurotransmitter serotonin from the synaptic cleft into presynaptic neurons for recycling, thus terminating its action [9,10]. Hence, 5HTT is involved in the serotonergic neurotransmission regulation by mediating the serotonin availability to other serotonergic systems[9][10].

    5HTTLPR-VNTR is one of the described genetic variants of the SLC6A4 gene. Located on human chromosome 17q11.2, this polymorphism is biallelic with a 44 bp insertion/deletion flanking the 5′ promoter region of the gene that gives rise to two different alleles: a long allele (Long, L), which contain the insertion, and a short allele (Short, S), which contain the deletion[9][11][12]. Population genetic studies have shown that the S allele presence decreases the 5HTT promoter gene’s transcriptional efficiency, resulting in a lower serotonin transporter binding and its uptake[13]. Accordingly, this genetic alteration may increase the risk of susceptibility to psychiatric disorders, such as MDD[13].

    Along with the extensively studied 5HTTLPR-VNTR, the single nucleotide polymorphisms (SNP) rs25531 and rs25532, which refer to the same nucleotide located within the promoter region (5HTTLPR), implements a new variation into the allelic frequency and contributes to the alteration of the protein functionality[14]. The SNP rs25531 can modify the S allele and the L allele of the 5HTTLPR-VNTR variant, leading to allelic subtypes' appearance: Sa, Sl, La, Lg. The substitution of the nucleotide base (A/G) influences the transcriptional regulator AP2 (activation protein 2) functionality that normally acts as an activator or repressor of transcription. In the S, La, and Lg alleles, this SNP creates an AP2 binding site that exerts a repressive role on the SLC6A4 promoter activity, hence suppressing SLC6A4 transcription[14][15][16]

    HTTLPR Variant Genotypic Distribution in the Population

    Genetic variants may change according to the studied population. Accordingly, when analyzing the 5HTTLPR-VNTR variant in the selected articles, the S allele had a higher genotypic frequency. Whereas in the 5HTTLPR-rs25531 variant, the heterozygous LS genotype was the most frequent (Figure 1). As the 5HTTLPR-rs25531 variant can be present in the 5HTTLPR-VNTR variant, the authors grouped the variants to facilitate comprehension. According to Tatham et al.[17], the L’L’ group represents LA/LA; L’S’ represents a long allele and an efficient transcription (La/Lg or La/Sa) allele; and S’S’ represents two alleles with low transcriptional efficiency (Sa/Sa; Lg/Sa or Lg/Lg). While, Kao et al.[18] classified the variants as: S’S’ (Lg/Lg + Lg/S + S/S); L’S’ (La/Lg + Lg/S); L’L’ (La/La). SL will be for 5 HTTLPR-rs25531 and LS for 5HTTLPR-VNTR to facilitate the readers’ understanding.

    Figure 1. Genotypic distribution according to the number of articles found.

    In general, the S allele is present in 42% of Caucasians and 79% of Asians, while the L allele is much more frequent in Western populations than in Asian populations[14]. A Caucasian population study with 46 MDD patients and ages between 19 to 58 years has shown that the S allele of the 5HTTLPR-VNTR variant may be related to the increased risk of depression by negatively affecting the serotonin reuptake rate due to its low expression[19]. Mendonça et al.[20], in a study developed in Brazil, had the S allele as the most frequent in their sample, a result similar to Murdoch et al.[21] study in an Asian population, in which more than 60% of the MMD samples had the present allele. Hence, the S allele may be related to the depressive risk, plausibly due to its adverse effects on the serotonin reuptake rate[14]. Nevertheless, Kao et al.[18] found no correlation between the S allele and the risk of developing depression. 

    According to Sun et al.[22], the combination of the short and long allele of 5HTTLPR-VNTR in heterozygous individuals has a statistically higher chance of MDD development (OR = 1.42, p = 0.02) than those with homozygous genotype. Similar results were found in Turkish[23], Mexican[24], and Indian[25] populations.

    On the other hand, the 5HTTLPR-rs25531 variant expression is highly diversified among the distinct populations, as different genotypic frequencies may be detected within the same geographic region. These differing genotypic frequencies have been observed in studies in the North American population (Canada, United States of America, and Mexico) that demonstrated a variation in the SL genotypic domain[26][27], though this might also be due to the ethnicity variation in these regions.

    The 5HTTLPR-rs25531 S/La genotype was the most prominent in a study by Camarena et al.[20] with Mexican individuals (53 research participants). Jaworska et al. [34], in a study with a Canadian population, obtained an equivalent result but with a sample size of 20 participants. In two separate studies, Tatham et al.[19][17] found the L’S’ domain, representing one high and one low transcriptionally efficient alleles in most of their studied population (La/Lg ou La/Sa). A comparable result was attained by Ramasubb et al.[28], in which the La/Sa genotype was also more frequent.

    In Asia, a variety of genetic domains are seen within the same population. Basu et al.[29] found the 5HTTLPR-rs25531 SL genotype in MDD individuals from India. In contrast, Manoharan et al.[25] found a higher frequency of 5HTTLPR-rs25531 S/La genotype in the Indian population. Nonetheless, in a study with Chinese individuals, most research participants had the 5HTTLPR-rs25531 S’S’ genotype (Lg/Lg + Lg/S + SS). This S’S’ genotype, according to Kao et al.[18], had not been found in previous studies and was classified as a new genotypic domain.

    European studies are similar to the others, as they also found a higher frequency of the SL genotype[30]. By analyzing Dutch individuals’ genotypes, Fleurkens et al.[31] noted that 52% (n = 109) of the research participants had the La/Lg genotype. In another German study by Schneider et al.[32], however, the La/Sa genotype had a result similar to the study conducted in a Canadian population[19][17]. Thus, it can be inferred that these genotypes are found more frequently in those of European ancestry.

    The tremendous genetic variability seen in these studies attests that the world population’s genetic dissimilarity. Hence, research into allelic variations in different populations’ genetic background is critical in understanding the existing diseases and assisting in their prevention and treatment in each society.

    HTTLPR Variant and the Nervous System

    The nervous system is responsible for coordinating actions in the human body through chemical (neurotransmitter) and electrical signals between its cells. Among the more than fifty neurotransmitters described, serotonin (5-HT) stands out, as it is responsible for regulating sleep and mood[33][34].

    According to Han et al.[35], L allele carriers, in the 5HTTLPR-VNTR variant, obtained a significant reduction in the right anterior midcingulate gyrus (p = 0.001) and the cortical (p = 0.001) volume, in comparison to S allele homozygous individuals. Through a surgical cut of both lateral bundles of this rotation, it is possible to interrupt the neural Papez circuit communication and reduce the level of pre-existing nervous depression and anxiety; it can also aid with obsessive-compulsive disorder (OCD) treatment, chemical addiction, and chronic pain[36]. Therefore, this volume reduction in the patient with the L allele is considered a “protective factor”[35]. In contrast, the SS homozygous depressed patients’ hippocampal volumes were smaller than healthy controls in both hemispheres [34]. The effects of the 5HTTLPR on hippocampal volumes were also detected in OCD patients[37].

    Ancelin et al.[38] demonstrated that a lifetime of MDD was associated with persistent volume reductions in the deep nuclei, insular, thalamus, ventral diencephalon, pallidum, and nucleus accumbens and with a broader pericalcarine region in both men and women, and other gender and age-related changes. In regards to the 5HTTLPR genotype, Ancelin et al.[38] study found no significant volumetric differences according to 5HTTLPR within the groups with or without lifetime MDD but did find that the lifetime MDD and LL genotypes participants had smaller thalamus, while the lifetime MDD and SL genotypes participants had larger pericalcarine and lingual volumes compared with their non-MDD counterparts. Though these results should be taken into careful consideration as in younger populations, the S allele is perceived as a risk factor for mental and physical distress, whereas in older adults, the LL genotype appears to be a risk factor for those highly exposed to chronic disorders and severe stressors[39]

    Tatham et al.[17], in separate studies, evaluated the integrity of the brain white matter and reported increased lesions in 5HTTLPR-VNTR S’L’ heterozygous patients when compared to SS and LL homozygous. Furthermore, the interaction between fractional anisotropy in the uncinated fascicle on the right and 5HTTLPR altered the percentage in the severity of depression[17]. Additionally, the putamen and left thalamus region in the La/La homozygotes of the 5HTTLPR-rs25531 variant had a higher volume than the SS homozygotes and La/S heterozygotes, which could negatively related to behavior, complex and sequential motor planning, learning, cognitive, and motivational direction, and, in some cases, surgery is needed[40].

    Monoamine serotonin’s binding level to the 5HTT receptor is related to emotional processing, where a lower serotonin transporter binding is associated with psychiatric symptoms[26][41][42][43]. In a study coordinated by Schneck et al.[26], a higher reactivity of the right amygdala was associated with lower binding to the 5HTT raphe nucleus, but not to the 5HTTLPR genotype. Research on SLC6A4 AluJb methylation in MDD and amygdala reactivity, in addition to its associations with 5HTTLPR-rs25531 and stress, in depressed patients revealed that individuals with low methylation, in conjunction with a shorter MDD history and lower amygdala reactivity, may present an epigenetic process more adaptable to stress[13][14][32][44]. SLC6A4 hypermethylation has typically been described as independently associated with early stress and depressive disorders; though, very few studies address whether methylation can mediate the interaction between stress and 5HTTLPR in predicting psychopathological risk[13]. When assessing the association of raphe nuclei abnormal echogenicity in MDD patients’ brainstem, Kotisc et al.[30] detected a frequency of 66% of abnormality in MDD individuals.

    In synthesis, the 5HTTLPR genetic variant, be it VNTR or rs25531, has some role in the Nervous System in MDD patients.

    The entry is from 10.3390/genes11111260


    1. World Health Organization. Depression and other common mental disorders: global health estimates. World Heal Organ. 2017(link:;jsessionid=96DC05048E48EBF0BFF55ADF1A28292A?sequence=1; accessed on 1 October 2020)
    2. Iancu, S.C.; Wong, Y.M.; Rhebergen, D.; Van Balkom, A.J.L.M.; Batelaan, N.M. Long-term disability in major depressive disorder: a 6-year follow-up study. Psychol. Med. 2019, 50, 1644–1652, doi:10.1017/s0033291719001612.
    3. Ferrari, A.J.; Charlson, F.J.; Norman, R.E.; Patten, S.B.; Freedman, G.D.; Murray, C.J.; Vos, T.; Whiteford, H.A. Burden of Depressive Disorders by Country, Sex, Age, and Year: Findings from the Global Burden of Disease Study 2010. PLoS Med. 2013, 10, e1001547, doi:10.1371/journal.pmed.1001547.
    4. Wang, H.; Naghavi, M.; Allen, C.; Barber, R.M.; A Bhutta, Z.; Carter, A.; Casey, D.C.; Charlson, F.J.; Chen, A.Z.; Coates, M.M.; et al. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 2016, 388, 1459–1544, doi:10.1016/s0140-6736(16)31012-1.
    5. Flint J, Kendler K.S. The Genetics of Major Depression. Neuron. 2014; 81, 484–503.
    6. Otte, C.; Gold, S.M.; Penninx, B.W.; Pariante, C.M.; Etkin, A.; Fava, M.; Mohr, D.C.; Schatzberg, A.F. Major depressive disorder. Nat. Rev. Dis. Prim. 2016, 2, 16066, doi:10.1038/nrdp.2016.66.
    7. Howard, D.M.; Adams, M.J.; Clarke, T.-K.; Hafferty, J.D.; Gibson, J.; Shirali, M.; Coleman, J.R.I.; Hagenaars, S.P.; Ward, J.; Wigmore, E.M.; et al. Genome-wide meta-analysis of depression identifies 102 independent variants and highlights the importance of the prefrontal brain regions. Nat. Neurosci. 2019, 22, 343–352, doi:10.1038/s41593-018-0326-7.
    8. Shadrina, M.; Bondarenko, E.A.; Slominsky, P.A. Genetics Factors in Major Depression Disease. Front. Psychiatry 2018, 9, 334, doi:10.3389/fpsyt.2018.00334.
    9. NCBI. SLC6A4 solute carrier family 6 member 4 [Homo Sapiens (Human)] [Internet]. 2019. Available from: on 10 June 2020)
    10. Chen, F.-X.; Chen, X.-S.; Guo, J.-C.; Zheng, B.-A.; Guo, M. Serotonin transporter-linked polymorphic region genotypes in relation to stress conditions among patients with papillary thyroid carcinoma. Int J Clin Exp Pathol 2019, 12, 968–977.
    11. Lesch, K.-P.; Bengel, D.; Heils, A.; Sabol, S.Z.; Greenberg, B.D.; Petri, S.; Benjamin, J.; Müller, C.R.; Hamer, D.; Murphy, D.L. Association of Anxiety-Related Traits with a Polymorphism in the Serotonin Transporter Gene Regulatory Region. Sci. 1996, 274, 1527–1531, doi:10.1126/science.274.5292.1527.
    12. Ming, Q.; Zhang, Y.; Yi, J.; Wang, X.; Zhu, X.; Yao, S. Serotonin transporter gene polymorphism (5-HTTLPR) L allele interacts with stress to increase anxiety symptoms in Chinese adolescents: a multiwave longitudinal study. BMC Psychiatry 2015, 15, 1–8, doi:10.1186/s12888-015-0639-y.
    13. Palma-Gudiel, H.; Fañanás, L. An integrative review of methylation at the serotonin transporter gene and its dialogue with environmental risk factors, psychopathology and 5-HTTLPR. Neurosci. Biobehav. Rev. 2017, 72, 190–209, doi:10.1016/j.neubiorev.2016.11.011.
    14. Iurescia, S.; Seripa, D.; Rinaldi, M. Role of the 5-HTTLPR and SNP Promoter Polymorphisms on Serotonin Transporter Gene Expression: a Closer Look at Genetic Architecture and In Vitro Functional Studies of Common and Uncommon Allelic Variants. Mol. Neurobiol. 2015, 53, 5510–5526, doi:10.1007/s12035-015-9409-6.
    15. Hu, X.-Z.; Lipsky, R.H.; Zhu, G.; Akhtar, L.A.; Taubman, J.; Greenberg, B.D.; Xu, K.; Arnold, P.D.; Richter, M.A.; Kennedy, J.L.; et al. Serotonin Transporter Promoter Gain-of-Function Genotypes Are Linked to Obsessive-Compulsive Disorder. Am. J. Hum. Genet. 2006, 78, 815–826, doi:10.1086/503850.
    16. Kraft, J.B.; Slager, S.L.; McGrath, P.J.; Hamilton, S.P. Sequence Analysis of the Serotonin Transporter and Associations with Antidepressant Response. Biol. Psychiatry 2005, 58, 374–381, doi:10.1016/j.biopsych.2005.04.048.
    17. Tatham, E.L.; Ramasubbu, R.; Gaxiola-Valdez, I.; Cortese, F.; Clark, D.; Goodyear, B.; Foster, J.; Hall, G.B. White matter integrity in major depressive disorder: Implications of childhood trauma, 5-HTTLPR and BDNF polymorphisms. Psychiatry Res. Neuroimaging 2016, 253, 15–25, doi:10.1016/j.pscychresns.2016.04.014.
    18. Kao, W.-T.; Chang, C.-L.; Lung, F.-W. 5-HTT mRNA level as a potential biomarker of treatment response in patients with major depression in a clinical trial. J. Affect. Disord. 2018, 238, 597–608, doi:10.1016/j.jad.2018.06.035.
    19. Tatham, E.L.; Hall, G.B.C.; Clark, D.; Foster, J.; Ramasubbu, R. The 5-HTTLPR and BDNF polymorphisms moderate the association between uncinate fasciculus connectivity and antidepressants treatment response in major depression. Eur. Arch. Psychiatry Clin. Neurosci. 2016, 267, 135–147, doi:10.1007/s00406-016-0702-9.
    20. Mendonça, M.; Mangiavacchi, P.; Ferreira, P.D.S.; Crippa, J.; Mendes, A.; Loureiro, S.; Martín-Santos, R.; Quirino, C.; Kanashiro, M.; Rios, A. Epigenetic variation at the SLC6A4 gene promoter in mother–child pairs with major depressive disorder. J. Affect. Disord. 2019, 245, 716–723, doi:10.1016/j.jad.2018.10.369.
    21. Murdoch, J.D.; Speed, W.C.; Pakstis, A.J.; Heffelfinger, C.E.; Kidd, K.K. Worldwide Population Variation and Haplotype Analysis at the Serotonin Transporter Gene SLC6A4 and Implications for Association Studies. Biol. Psychiatry 2013, 74, 879–889, doi:10.1016/j.biopsych.2013.02.006.
    22. Sun, N.; Yang, C.-X.; Liu, Z.-F.; Li, X.-R.; Xu, Y.; Zhang, K. Effects of polymorphisms of serotonin transporter promoter (5-HTTLPR) and brain derived neurotrophic factor gene (G196A rs6265) on the risk of major depressive disorder in the Chinese Han population. Eur Rev Med Pharmacol Sci 2016, 20.
    23. Ozcurumez, G.; Yurdakul, H.T.; Terzi, Y.; Direk, N.; Essizoglu, A.; Sahin, F. No Interaction Between Childhood Maltreatment and Serotonin Transporter Gene in Recurrent Major Depressive Disorder: A Clinical Sample. Arch. Neuropsychiatry 2019, 56, 110–114, doi:10.29399/npa.23325.
    24. Basu, A.; Chadda, R.; Sood, M.; Kaur, H.; Kukreti, R. A preliminary association study between serotonin transporter (5-HTTLPR), receptor polymorphisms (5-HTR1A, 5-HTR2A) and depression symptom-clusters in a north Indian population suffering from Major Depressive Disorder (MDD). Asian J. Psychiatry 2019, 43, 184–188, doi:10.1016/j.ajp.2019.05.028.
    25. Manoharan, A.; Shewade, D.G.; Rajkumar, R.P.; Chandrasekaran, A. Serotonin transporter gene (SLC6A4) polymorphisms are associated with response to fluoxetine in south Indian major depressive disorder patients. Eur. J. Clin. Pharmacol. 2016, 72, 1215–1220, doi:10.1007/s00228-016-2099-9.
    26. Schneck, N.; Mann, J.J.; DeLorenzo, C.; Kikuchi, T.; Sublette, M.E.; Oquendo, M.A.; Mann, J.J.; Parsey, R.V. Relationship of the serotonin transporter gene promoter polymorphism (5-HTTLPR) genotype and serotonin transporter binding to neural processing of negative emotional stimuli. J. Affect. Disord. 2015, 190, 494–498, doi:10.1016/j.jad.2015.10.047.
    27. Talati, A.; Odgerel, Z.; Wickramaratne, P.J.; Norcini-Pala, A.; Skipper, J.L.; Gingrich, J.A.; Weissman, M.M. Associations between serotonin transporter and behavioral traits and diagnoses related to anxiety. Psychiatry Res. 2017, 253, 211–219, doi:10.1016/j.psychres.2017.03.033.
    28. Ramasubbu, R.; Burgess, A.; Gaxiola-Valdez, I.; Cortese, F.; Clark, D.; Kemp, A.; Goodyear, B.; MacQueen, G.; Bech-Hansen, N.T.; Foster, J.; et al. Amygdala responses to quetiapine XR and citalopram treatment in major depression: the role of 5-HTTLPR-S/Lg polymorphisms. Hum. Psychopharmacol. Clin. Exp. 2016, 31, 144–155, doi:10.1002/hup.2521.
    29. Camarena, B.; Álvarez-Icaza, D.; Hernández, S.; Aguilar, A.; Münch, L.; Martínez, C.; Becerra-Palars, C. Association Study Between Serotonin Transporter Gene and Fluoxetine Response in Mexican Patients With Major Depressive Disorder. Clin. Neuropharmacol. 2019, 42, 9–13, doi:10.1097/wnf.0000000000000315.
    30. Kostić, M.; Munjiza, A.; Pesic, D.; Peljto, A.; Novakovic, I.; Dobricic, V.; Tosevski, D.L.; Mijajlovic, M. A pilot study on predictors of brainstem raphe abnormality in patients with major depressive disorder. J. Affect. Disord. 2017, 209, 66–70, doi:10.1016/j.jad.2016.11.034.
    31. Fleurkens, P.; Van Minnen, A.; Becker, E.S.; Van Oostrom, I.; Speckens, A.; Rinck, M.; Vrijsen, J.N. Automatic approach-avoidance tendencies as a candidate intermediate phenotype for depression: Associations with childhood trauma and the 5-HTTLPR transporter polymorphism. PLOS ONE 2018, 13, e0193787, doi:10.1371/journal.pone.0193787.
    32. Schneider, I.; Kugel, H.; Redlich, R.; Grotegerd, D.; Bürger, C.; Bürkner, P.-C.; Opel, N.; Dohm, K.; Zaremba, D.; Meinert, S.; et al. Association of Serotonin Transporter Gene AluJb Methylation with Major Depression, Amygdala Responsiveness, 5-HTTLPR/rs25531 Polymorphism, and Stress. Neuropsychopharmacol. 2017, 43, 1308–1316, doi:10.1038/npp.2017.273.
    33. Sun, X.; Li, C.; Zhong, X.; Dong, D.; Ming, Q.; Gao, Y.; Xiong, G.; Cheng, C.; Zhao, H.; Wang, X.; et al. Influence of psychosocial stress on activation in human brain regions: moderation by the 5-HTTLPR genetic locus. Physiol. Behav. 2020, 220, 112876, doi:10.1016/j.physbeh.2020.112876.
    34. Eker, M.; Kitis, O.; Okur, H.; Eker, O.D.; Ozan, E.; Isikli, S.; Akarsu, N.; Gonul, A.S. Smaller Hippocampus Volume Is Associated with Short Variant of 5-HTTLPR Polymorphism in Medication-Free Major Depressive Disorder Patients. Neuropsychobiology 2011, 63, 22–28, doi:10.1159/000321834.
    35. Han, K.-M.; Choi, S.; Kim, A.; Kang, J.; Won, E.; Tae, W.S.; Kim, Y.-K.; Lee, M.-S.; Ham, B.-J. The effects of 5-HTTLPR and BDNF Val66Met polymorphisms on neurostructural changes in major depressive disorder. Psychiatry Res. Neuroimaging 2018, 273, 25–34, doi:10.1016/j.pscychresns.2018.01.005.
    36. Wilkinson, H.A.; Davidson, K.M.; Davidson, R.I. Bilateral anterior cingulotomy for chronic noncancer pain. Neurosurg. 1999, 45, 1129–1136, doi:10.1097/00006123-199911000-00023.
    37. Honda, S.; Nakao, T.; Mitsuyasu, H.; Okada, K.; Gotoh, L.; Tomita, M.; Sanematsu, H.; Murayama, K.; Ikari, K.; Kuwano, M.; et al. A pilot study exploring the association of morphological changes with 5-HTTLPR polymorphism in OCD patients. Ann. Gen. Psychiatry 2017, 16, 2, doi:10.1186/s12991-017-0126-6.
    38. Ancelin, M.-L.; Carrière, I.; Artero, S.; Maller, J.; Meslin, C.; Ritchie, K.; Ryan, J.; Chaudieu, I. Lifetime major depression and grey-matter volume. J. Psychiatry Neurosci. 2019, 44, 45–53, doi:10.1503/jpn.180026.
    39. Grabe, H.J.; Schwahn, C.; Appel, K.; Mahler, J.; Schulz, A.; Spitzer, C.; Barnow, S.; John, U.; Freyberger, H.J.; Rosskopf, D.; et al. Update on the 2005 paper: moderation of mental and physical distress by polymorphisms in the 5-HT transporter gene by interacting with social stressors and chronic disease burden. Mol. Psychiatry 2010, 16, 354–356, doi:10.1038/mp.2010.45.
    40. Jaworska, N.; MacMaster, F.P.; Foster, J.A.; Ramasubbu, R. The influence of 5-HTTLPR and Val66Met polymorphisms on cortical thickness and volume in limbic and paralimbic regions in depression: a preliminary study. BMC Psychiatry 2016, 16, 61, doi:10.1186/s12888-016-0777-x.
    41. Zoons, E.; Booij, J.; Speelman, J.D.; Dreissen, Y.E.M.; Smit, M.; Tijssen, M.A.J. Lower serotonin transporter binding in patients with cervical dystonia is associated with psychiatric symptoms. EJNMMI Res. 2017, 7, 1–7, doi:10.1186/s13550-017-0338-4.
    42. Mann, J.J.; Kinnally, E.L.; Ogden, R.T.; Oquendo, M.A.; Mann, J.J.; Parsey, R.V. Reported childhood abuse is associated with low serotonin transporter binding in vivo in major depressive disorder. Synap. 2009, 63, 565–573, doi:10.1002/syn.20637.
    43. 50. Lindström MB, Ryding E, Bosson P, Ahnlide JA, Rosén I, Träskman-Bendz L. Impulsivity related to brain serotonin transporter binding capacity in suicide attempters. Eur Neuropsychopharmacol. 2004;14(4):295–300.
    44. Bleys, D.; Luyten, P.; Soenens, B.; Claes, S. Gene-environment interactions between stress and 5-HTTLPR in depression: A meta-analytic update. J. Affect. Disord. 2018, 226, 339–345, doi:10.1016/j.jad.2017.09.050.